As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
7 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:
7 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -18 -18 |
17%
17%
|
|
| EBIT (Operating Income) EBIT | -18 -18 |
17%
17%
|
|
| Net Profit | -13 -13 |
6%
6%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.
| Head office | United Kingdom |
| CEO | Mr. Elrifi |
| Employees | 9 |
| Founded | 1998 |
| Website | www.tizianalifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


